Vetter Commits to New Production Facility in Germany
The CDMO commits EUR 480 million to a new production facility on its Saarlouis site as it puts into action its long-term growth strategy to meet rising global biopharma demand.
A EUR 480 million investment has been unveiled by global CDMO, Vetter, which will be used to establish a new production facility in Saarlouis, Germany. The company’s investment will also be supported by up to EUR 47 million in state aid approved by the European Commission.
According to a company press release about the investment, the site had been chosen by Vetter, after extensive evaluations, for its strong infrastructure and skilled local workforce. The production facility project is expected to create as many as 2,000 jobs, once construction begins in Q2 2026 (1).
Vetter positions the new facility as a key pillar of its long-term growth strategy amid rising demand from its global biopharma customers. With the new commercial capacity in Germany, the company is set to strengthen its role as a strategic partner to the pharmaceutical industry while reinforcing its commitment to the German manufacturing base.
“With the construction of our new production facility in Germany, we continue on our path to sustainable growth,” said Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and member of the owner family, in the company press release (1). “Long-term success derives from striking the right balance between stability and expansion. With our investments in the state of Saarland, only a five-hour drive away from our headquarters in Ravensburg, we are strengthening our commitment to Germany’s economic landscape while reaffirming our engagement as a strategic partner to the global pharmaceutical market.”
In parallel with the Saarland project, Vetter has also started construction on a new clinical production site in Des Plaines, Illinois, USA, breaking ground on the new site back in June 2025 (2). The U.S.-based aseptic manufacturing facility will support high-quality drug product supply during early clinical development and expand capacity for customers progressing novel therapies through first-in-human and proof-of-concept studies.
“This project marks another milestone in our international growth strategy,” explained Vetter in a press release about the groundbreaking ceremony for the U.S. site (2). “It underscores our commitment to quality and innovation, as well as our responsibility to our customers, partners, and patients around the world.”
The investments in both commercial and clinical manufacturing build on Vetter’s more than 75-year history in the production of sterile pharmaceuticals, during which time the company has focused on quality, innovation, and long-term customer partnerships. Alongside the new facilities, the CDMO is continuing to invest in its existing sites in Germany, Austria, and the U.S. to meet growing demand and evolving market requirements for injectable drug products.
References
Vetter. We are Building a New Location in Saarland. Press Release, Jan. 28, 2026.
Vetter. Vetter Marks the Start of New Clinical Site Construction with Groundbreaking Ceremony. Press Release, June 27, 2025.